Loading clinical trials...
Loading clinical trials...
Safety, Tolerability and Pharmacokinetics of Single-ascending Doses of RCS-21 in Healthy Volunteers. A Double Blind, Randomized, Placebo Controlled Phase I Study.
Conditions
Interventions
Placebo (SAD)
RCS-21 (SAD)
Locations
1
Germany
Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
Hanover, Germany
Start Date
February 18, 2025
Primary Completion Date
June 1, 2026
Completion Date
August 1, 2026
Last Updated
November 20, 2025
NCT00104325
NCT05937750
NCT07118891
NCT01399385
NCT07295717
NCT03807401
Lead Sponsor
RNATICS GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions